ImmunoGen, Inc. (NASDAQ:IMGN)

CAPS Rating: 3 out of 5

The Company develops antibody-based anticancer therapeutics.

Recs

0
Player Avatar MicroMagic (53.84) Submitted: 8/31/2012 7:02:48 PM : Outperform Start Price: $14.43 IMGN Score: -5.82

I like their pipeline, there's no specific catalyst, that I'm aware of to pick this baby now. Perhaps in 5 years this will be more than a multibagger.

I like the chances with this one.

Report this Post Reply

Featured Broker Partners


Advertisement